首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2032650

胃癌治療市場報告：按類型、給藥途徑、最終用戶和地區分類（2026-2034 年）

Gastric Cancer Drugs Market Report by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2026-2034

出版日期: 2026年04月01日 | 出版商:

IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2025年，全球胃癌治療市場規模達57億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到141億美元，2026年至2034年的複合年成長率為10.27%。全球人口老化加劇和肥胖率上升是推動市場擴張的主要因素。

胃癌治療市場的發展趨勢：

生物相似藥的興起

胃癌生物相似藥的研發正在穩步推進，為昂貴的生物製藥提供了經濟有效的替代方案，並有助於各國患者獲得創新療法。 2024年7月，Zydus Lifesciences公司獲得墨西哥監管機構核准，銷售用於治療乳癌和胃癌的曲妥珠單抗生物相似藥Mamitra，進一步拓展了其生物相似藥產品系列。

免疫療法的進展

人們對免疫療法藥物，尤其是免疫查核點抑制劑的興趣日益濃厚，這推動了胃癌治療的研究。這些藥物能夠增強免疫系統對癌細胞的反應，為傳統化療提供了一個新的選擇。 2024年10月，百濟神州獲得美國食品藥物管理局（FDA）核准後，在美國推出了PD-1抑制劑Tevinbra，價格比默克公司的Keytruda低10%。

社區臨床試驗數量增加

區域性臨床試驗的激增正在推動藥物創新和治療方案的進步。針對特定患者群體和基因譜的個人化治療正在提高全球胃癌治療的有效性和適宜性。 2024年10月發表在《新英格蘭日誌雜誌》上的一項新研究顯示，接受歐洲核准的佐貝妥昔單抗治療的胃癌患者的生存率更高。

市場結構
大公司
主要公司簡介
- Abbott Laboratories
- Arog Pharmaceuticals Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eli Lilly and company
- F. Hoffmann-La Roche AG
- Ono Pharmaceutical Co. Ltd.
- Sanofi SA
- Taiho Pharmaceutical Co. Ltd.（Otsuka Pharmaceutical Co. Ltd.）

簡介目錄圖表

Product Code: SR112026A6648

The global gastric cancer drugs market size reached USD 5.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 10.27% during 2026-2034. The expanding geriatric population and the rising incidence of obesity across the world are stimulating the market.

GASTRIC CANCER DRUGS MARKET ANALYSIS:

Major Market Drivers: The increasing frequency of both acute and chronic indications, the rising weight-related health issues, and the growing awareness about health consciousness are propelling the market.
Key Market Trends: Rapid technological breakthroughs focused on the development of effective and tailored cancer treatments are contributing to the gastric cancer drugs market growth.
Competitive Landscape: Some of the major market companies include Abbott Laboratories, Arog Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), among many others.
Geographical Trends: Asia Pacific is currently dominating the market due to the rising prevalence of gastric cancer, attributed to factors such as poor dietary intake, Helicobacter pylori infections, and an aging population, which is increasing the need for effective treatments.
Challenges and Opportunities: The high cost of advanced treatments is hampering the market. However, collaborations between governments and pharmaceutical corporations to lower costs and increase affordability will continue to catalyze the market over the forecast period.

GASTRIC CANCER DRUGS MARKET TRENDS:

Rise of Biosimilars

The development of biosimilars for gastric cancer medications is expanding, providing cost-effective alternatives to costly biologics and boosting access to innovative treatments in a variety of countries. In July 2024, Zydus Lifesciences received Mexican regulatory approval to market Mamitra, a trastuzumab biosimilar for breast and gastric cancer treatment, expanding its biosimilar portfolio.

Growth in Advancements in Immunotherapy

The increasing focus on immunotherapy medications, particularly immune checkpoint inhibitors, is driving treatment research for gastric cancer. These medicines boost the immune system's reaction to cancer cells, providing intriguing alternatives to traditional chemotherapy. In October 2024, BeiGene launched the PD-1 cancer drug Tevimbra in the U.S. at a 10% discount to Merck's Keytruda after receiving FDA approval.

Increase in Localized Clinical Trials

A surge in localized clinical trials is driving medication innovation and treatment protocols, with an emphasis on personalizing medicines to specific populations and genetic profiles, thereby boosting the effectiveness and relevance of gastric cancer treatments worldwide. In October 2024, a new study published in the New England Journal of Medicine revealed that gastric cancer patients treated with zolbetuximab, a medicine approved in Europe, had higher survival rates.

GLOBAL GASTRIC CANCER DRUGS INDUSTRY SEGMENTATION:

Breakup by Type:

Doxorubicin Hydrochloride
Sunitinib
Docetaxel
Mitomycin
Fluorouracil
Imatinib
Trastuzumab

Currently, trastuzumab holds the largest gastric cancer drugs market share

Trastuzumab is a monoclonal antibody that cures HER2-positive gastric cancer by targeting the HER2 protein, which improves patient outcomes and increases survival when combined with chemotherapy.

Breakup by Route of Administration:

Oral
Parenteral

Among these, parenteral holds the largest gastric cancer drugs market size

Parenteral administration, such as intravenous infusion, is widely utilized for chemotherapy and targeted therapies, providing quick drug absorption and efficacy in advanced gastric cancer cases.

Breakup by End User:

Hospitals
Clinics
Others

Currently, hospitals dominate the market with the largest gastric cancer drugs market share

Hospitals continue to be important end users, offering modern treatments such as chemotherapy, immunotherapy, and targeted medicines, as well as comprehensive cancer care through specialized oncology departments.

Breakup by Region:

North America
- United States
- Canada
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Asia Pacific leads in the gastric cancer drugs market growth

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest gastric cancer drugs market share.

Asia Pacific exhibits a clear dominance in the market driven by government initiatives aimed at improving cancer care and increasing healthcare spending. Furthermore, pharmaceutical corporations are also heavily spending on research and development, resulting in the introduction of new therapies such as targeted treatments and immunotherapy, which are gaining popularity.

COMPETITIVE LANDSCAPE:

The report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

Abbott Laboratories
Arog Pharmaceuticals Inc.
Bristol-Myers Squibb Company
Daiichi Sankyo Company Limited
Eli Lilly and Company
F. Hoffmann-La Roche AG
Ono Pharmaceutical Co. Ltd.
Sanofi S.A.
Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Gastric Cancer Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Doxorubicin Hydrochloride
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Sunitinib
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Docetaxel
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Mitomycin
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Fluorouracil
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Imatinib
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 Trastuzumab
- 6.7.1 Market Trends
- 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Parenteral
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Arog Pharmaceuticals Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
- 14.3.3 Bristol-Myers Squibb Company
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Daiichi Sankyo Company Limited
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Eli Lilly and company
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche AG
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
- 14.3.7 Ono Pharmaceutical Co. Ltd.
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Sanofi S.A.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Gastric Cancer Drugs Market: Major Drivers and Challenges
Figure 2: Global: Gastric Cancer Drugs Market: Sales Value (in Billion USD), 2020-2025
Figure 3: Global: Gastric Cancer Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
Figure 4: Global: Gastric Cancer Drugs Market: Breakup by Type (in %), 2025
Figure 5: Global: Gastric Cancer Drugs Market: Breakup by Route of Administration (in %), 2025
Figure 6: Global: Gastric Cancer Drugs Market: Breakup by End User (in %), 2025
Figure 7: Global: Gastric Cancer Drugs Market: Breakup by Region (in %), 2025
Figure 8: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market: Sales Value (in Million USD), 2020 & 2025
Figure 9: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 10: Global: Gastric Cancer Drugs (Sunitinib) Market: Sales Value (in Million USD), 2020 & 2025
Figure 11: Global: Gastric Cancer Drugs (Sunitinib) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 12: Global: Gastric Cancer Drugs (Docetaxel) Market: Sales Value (in Million USD), 2020 & 2025
Figure 13: Global: Gastric Cancer Drugs (Docetaxel) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 14: Global: Gastric Cancer Drugs (Mitomycin) Market: Sales Value (in Million USD), 2020 & 2025
Figure 15: Global: Gastric Cancer Drugs (Mitomycin) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 16: Global: Gastric Cancer Drugs (Fluorouracil) Market: Sales Value (in Million USD), 2020 & 2025
Figure 17: Global: Gastric Cancer Drugs (Fluorouracil) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 18: Global: Gastric Cancer Drugs (Imatinib) Market: Sales Value (in Million USD), 2020 & 2025
Figure 19: Global: Gastric Cancer Drugs (Imatinib) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 20: Global: Gastric Cancer Drugs (Trastuzumab) Market: Sales Value (in Million USD), 2020 & 2025
Figure 21: Global: Gastric Cancer Drugs (Trastuzumab) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 22: Global: Gastric Cancer Drugs (Oral) Market: Sales Value (in Million USD), 2020 & 2025
Figure 23: Global: Gastric Cancer Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 24: Global: Gastric Cancer Drugs (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
Figure 25: Global: Gastric Cancer Drugs (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 26: Global: Gastric Cancer Drugs (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
Figure 27: Global: Gastric Cancer Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 28: Global: Gastric Cancer Drugs (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
Figure 29: Global: Gastric Cancer Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 30: Global: Gastric Cancer Drugs (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
Figure 31: Global: Gastric Cancer Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 32: North America: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 33: North America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 34: United States: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 35: United States: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 36: Canada: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 37: Canada: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 38: Asia-Pacific: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 39: Asia-Pacific: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 40: China: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 41: China: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 42: Japan: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 43: Japan: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 44: India: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 45: India: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 46: South Korea: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 47: South Korea: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 48: Australia: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 49: Australia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 50: Indonesia: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 51: Indonesia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 52: Others: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 53: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 54: Europe: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 55: Europe: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 56: Germany: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 57: Germany: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 58: France: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 59: France: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 60: United Kingdom: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 61: United Kingdom: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 62: Italy: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 63: Italy: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 64: Spain: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 65: Spain: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 66: Russia: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 67: Russia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 68: Others: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 69: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 70: Latin America: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 71: Latin America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 72: Brazil: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 73: Brazil: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 74: Mexico: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 75: Mexico: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 76: Others: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 77: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 78: Middle East and Africa: Gastric Cancer Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 79: Middle East and Africa: Gastric Cancer Drugs Market: Breakup by Country (in %), 2025
Figure 80: Middle East and Africa: Gastric Cancer Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 81: Global: Gastric Cancer Drugs Industry: Drivers, Restraints, and Opportunities
Figure 82: Global: Gastric Cancer Drugs Industry: Value Chain Analysis
Figure 83: Global: Gastric Cancer Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Gastric Cancer Drugs Market: Key Industry Highlights, 2025 & 2034
Table 2: Global: Gastric Cancer Drugs Market Forecast: Breakup by Type (in Million USD), 2026-2034
Table 3: Global: Gastric Cancer Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
Table 4: Global: Gastric Cancer Drugs Market Forecast: Breakup by End User (in Million USD), 2026-2034
Table 5: Global: Gastric Cancer Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 6: Global: Gastric Cancer Drugs Market: Competitive Structure
Table 7: Global: Gastric Cancer Drugs Market: Key Players

02-2729-4219

+886-2-2729-4219